Does Medicare Cover Ozempic and Wegovy in 2026? What to Know Before July 1
Starting July 1, 2026 — just 15 days from now — Medicare will cover GLP-1 weight loss medications including Ozempic and Wegovy for the first time. The monthly cost to eligible beneficiaries drops to a $50 cap. All 67 million Medicare enrollees become potentially eligible.
If you've been watching the price tag on semaglutide and waiting for an opening, this is it.
Here's exactly what's changing, who qualifies, what it actually costs, and what you need to do before the end of the month to get ahead of what will almost certainly be a massive surge in demand.
What's Actually Changing on July 1
Medicare has covered Ozempic for years — but only when prescribed to treat Type 2 diabetes. The drug's manufacturer, Novo Nordisk, sells the same active ingredient (semaglutide) under the brand name Wegovy at a higher dose specifically for obesity and weight management. Until now, Medicare was legally prohibited from covering drugs prescribed primarily for weight loss.
That prohibition ends July 1, 2026.
Under the new coverage expansion, Medicare Part D plans must cover GLP-1 receptor agonists when prescribed for obesity or weight management — not just for diabetes. For the first time, a beneficiary whose doctor prescribes Wegovy for weight loss, with no diabetes diagnosis required, can have that prescription covered.
The maximum out-of-pocket cost to you: $50 per month.
This is the largest single expansion of Medicare drug coverage for weight management since the program's creation. It affects an estimated 67 million Medicare enrollees.
Why This Matters More Than You Think
Ozempic and Wegovy work. That's not marketing — it's what the clinical data shows, consistently and clearly.
In the landmark SURMOUNT and STEP trial programs, participants taking semaglutide lost an average of 15–17% of their body weight over 68 weeks. At the highest doses tested, some groups averaged over 20% total body weight loss. These are numbers that rival bariatric surgery in some populations, without the surgical risk.
For people over 60, the implications go beyond aesthetics. Excess weight is a documented risk factor for Type 2 diabetes, cardiovascular disease, sleep apnea, osteoarthritis, and several cancers. Meaningful weight loss reduces cardiovascular events, improves blood sugar control, eases joint load, and in multiple studies, has shown improvements in markers associated with cognitive health.
The barrier has never been whether these drugs work. It's been whether people could afford them. Without insurance, Wegovy lists at over $1,300 per month. Even with commercial insurance coverage, many plans required prior authorizations that took months and were frequently denied.
At $50 a month through Medicare, that barrier falls significantly.
Who Qualifies for Medicare GLP-1 Coverage
Eligibility for the new GLP-1 coverage under Medicare works at two levels: you must be a Medicare beneficiary, and your physician must prescribe the medication within covered criteria.
Medicare eligibility is straightforward — if you're enrolled in Medicare Part D (prescription drug coverage), you are in the pool of 67 million newly eligible beneficiaries.
Prescription criteria is where individual plans may vary. While CMS (the Centers for Medicare & Medicaid Services) has set the $50 monthly cap and required coverage for GLP-1s, each Part D plan retains some discretion over prior authorization requirements. Generally, you can expect your prescriber will need to document:
- A diagnosis of obesity (typically defined as BMI ≥ 30) or overweight with at least one related health condition (BMI ≥ 27 with conditions such as hypertension, high cholesterol, or cardiovascular disease)
- That weight management through GLP-1 therapy is medically appropriate for you
- In some plans, evidence of prior attempts at diet and exercise modification
If you already have Type 2 diabetes and take Ozempic: Your coverage pathway hasn't changed — you were already covered. But if you've been considering switching to Wegovy at a higher dose for stronger weight loss effects, that transition may now be covered as well. Talk to your prescriber.
If you have Medicare Advantage (Part C): Coverage rules vary by plan. Starting July 1, most Advantage plans are required to follow the new GLP-1 coverage mandate, but call your plan directly to confirm your specific benefits before your next appointment.
What It Costs: The $50 Cap Explained
Under the new structure, your monthly cost for a covered GLP-1 medication is capped at $50. This applies to the maintenance dose phase of treatment — meaning once you're established on your full prescribed dose.
A few things to understand about how this plays out in practice:
The cap covers the drug itself. It does not cover the cost of your physician visits, lab work, nutritionist consultations, or any ancillary care your doctor recommends as part of your weight management plan. Those services are billed separately through Medicare Part B or your supplemental coverage.
Titration period costs may differ. GLP-1 medications are introduced gradually — you start at a low dose and increase over weeks or months to minimize side effects. Some Part D plans structure cost-sharing differently during the titration phase. Ask your pharmacist specifically about costs for the starter doses versus the maintenance dose.
Prior authorization may add time, not cost. If your plan requires prior authorization, there may be a lag between your prescription being written and coverage kicking in. Start this process immediately — don't wait until July 1 to begin the authorization paperwork if your doctor is ready to prescribe now.
Generic availability: As of mid-2026, brand-name Ozempic and Wegovy remain the primary covered options. The compounded semaglutide that many online pharmacies sold during prior shortages is not covered under Medicare and comes with its own risks. Stick to FDA-approved brand-name medications through a licensed pharmacy for Medicare coverage to apply.
Side Effects: What to Expect Honestly
GLP-1 medications are effective, but they're not without tradeoffs. Anyone starting — or considering starting — should have a realistic picture.
Common and expected:
- Nausea, particularly in the first several weeks as the dose increases
- Vomiting, constipation, or diarrhea in the adjustment period
- Reduced appetite (this is the mechanism — it's expected)
- Fatigue in some patients during dose escalation
Most GI side effects improve significantly after the first 4–8 weeks as the body adjusts. The standard advice — eat smaller portions, go slow on portions of rich or fatty food, stay hydrated — helps substantially.
Less common but worth knowing:
- Muscle loss: GLP-1s can cause loss of both fat and lean muscle mass. This is one of the most important things to manage actively. Resistance training and high-protein diet during the weight loss phase are consistently recommended by prescribers to preserve muscle.
- Pancreatitis: Rare but serious. If you develop severe upper abdominal pain radiating to your back, contact your doctor immediately.
- Thyroid concerns: Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use semaglutide. Your prescriber will screen for this.
- "Ozempic face": Rapid weight loss at any age can result in facial volume loss. For older adults, this is worth discussing with your doctor as part of setting realistic expectations.
A note on protein during GLP-1 treatment: Because appetite suppression reduces total food intake significantly, it becomes harder to hit adequate daily protein targets. A high-quality protein supplement taken daily can help you maintain lean mass while losing fat — this is genuinely important, not optional, for people over 55.
We recommend Transparent Labs Grass-Fed Whey Protein for people on GLP-1 therapy. It delivers 28g of clean protein per serving with no artificial additives, mixes easily, and holds up well even on reduced-appetite days when a full meal isn't appealing.
Affiliate Disclosure: This article may contain affiliate links. If you make a purchase through these links, we may earn a small commission at no extra cost to you. We only recommend products we genuinely believe in. This helps support our work and allows us to continue providing free content.
Avoid alcohol. Alcohol amplifies nausea significantly on GLP-1 therapy. Most people find they don't want it anyway due to reduced appetite, but it's worth going in with that expectation set.
The Bigger Picture: What This Means for You
If you've struggled with weight for years, cycled through diets, and felt like the system wasn't built for you — this policy change is meaningful. These medications do something diet alone often can't: they change the hunger signals that drive overeating, making sustained caloric reduction more achievable without constant willpower.
That doesn't mean they're magic. They work best as part of a full approach — protein-forward eating, regular movement, sleep, and stress management. What they do is remove the hardest obstacle: the constant, grinding biological pull of hunger.
At $50 a month through Medicare, this class of medication is now accessible to the people who arguably need it most. Don't wait for the July 1 surge. Start the process this week.
Last updated: 2026-06-16
Start Your Weight Loss Journey
Get our free GLP-1 Starter Guide — what to eat, what to expect, and how to make the most of the first 90 days of therapy.